SEASTAR MEDICAL HOLDING CORP (ICU) Stock Overview
USA - NASDAQ:ICU - US81256L2034 - Common Stock
ICU Key Statistics, Chart & Performance
The current stock price of ICU is 0.557 USD. In the past month the price increased by 37.92%. In the past year, price decreased by -71.03%.
ICU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.22 | 232.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 54.44 | 157.10B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.59 | 145.07B | ||
| SYK | STRYKER CORP | 28.61 | 140.54B | ||
| MDT | MEDTRONIC PLC | 17.02 | 120.71B | ||
| BDX | BECTON DICKINSON AND CO | 12.66 | 51.77B | ||
| IDXX | IDEXX LABORATORIES INC | 51.44 | 49.42B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.3 | 44.20B | ||
| RMD | RESMED INC | 28.01 | 39.16B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.62B | ||
| DXCM | DEXCOM INC | 40.21 | 26.80B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.71 | 25.56B |
Related stock screener links
About ICU
Company Profile
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Company Info
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 19
Phone: 18444278100
SEASTAR MEDICAL HOLDING CORP / ICU FAQ
What is the stock price of SEASTAR MEDICAL HOLDING CORP today?
The current stock price of ICU is 0.557 USD. The price decreased by -55.08% in the last trading session.
What is the ticker symbol for SEASTAR MEDICAL HOLDING CORP stock?
The exchange symbol of SEASTAR MEDICAL HOLDING CORP is ICU and it is listed on the Nasdaq exchange.
On which exchange is ICU stock listed?
ICU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SEASTAR MEDICAL HOLDING CORP stock?
5 analysts have analysed ICU and the average price target is 2.04 USD. This implies a price increase of 266.25% is expected in the next year compared to the current price of 0.557. Check the SEASTAR MEDICAL HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SEASTAR MEDICAL HOLDING CORP worth?
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 15.55M USD. This makes ICU a Nano Cap stock.
How many employees does SEASTAR MEDICAL HOLDING CORP have?
SEASTAR MEDICAL HOLDING CORP (ICU) currently has 19 employees.
What are the support and resistance levels for SEASTAR MEDICAL HOLDING CORP (ICU) stock?
SEASTAR MEDICAL HOLDING CORP (ICU) has a support level at 0.91. Check the full technical report for a detailed analysis of ICU support and resistance levels.
Is SEASTAR MEDICAL HOLDING CORP (ICU) expected to grow?
The Revenue of SEASTAR MEDICAL HOLDING CORP (ICU) is expected to grow by 509.96% in the next year. Check the estimates tab for more information on the ICU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SEASTAR MEDICAL HOLDING CORP (ICU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICU, evaluating the profitability, health, valuation and growth aspects
- SEASTAR MEDICAL HOLDING CORP (ICU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SEASTAR MEDICAL HOLDING CORP (ICU) Sales and EPS estimates to see what analysts future expectations are.
- SEASTAR MEDICAL HOLDING CORP (ICU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SEASTAR MEDICAL HOLDING CORP (ICU) Insider and Institutional Ownership to learn about the owners and their transactions.
- SEASTAR MEDICAL HOLDING CORP (ICU) Stock Chart to make your own analysis
- SEASTAR MEDICAL HOLDING CORP (ICU) Latest news and press-releases to stay up to date.
Does SEASTAR MEDICAL HOLDING CORP (ICU) stock pay dividends?
ICU does not pay a dividend.
When does SEASTAR MEDICAL HOLDING CORP (ICU) report earnings?
SEASTAR MEDICAL HOLDING CORP (ICU) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of SEASTAR MEDICAL HOLDING CORP (ICU)?
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
What is the Short Interest ratio of SEASTAR MEDICAL HOLDING CORP (ICU) stock?
The outstanding short interest for SEASTAR MEDICAL HOLDING CORP (ICU) is 11.32% of its float. Check the ownership tab for more information on the ICU short interest.
ICU Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ICU. When comparing the yearly performance of all stocks, ICU is one of the better performing stocks in the market, outperforming 93.84% of all stocks.
ICU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICU. The financial health of ICU is average, but there are quite some concerns on its profitability.
ICU Financial Highlights
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS increased by 87.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.01% | ||
| ROE | -439.12% | ||
| Debt/Equity | 0 |
ICU Forecast & Estimates
5 analysts have analysed ICU and the average price target is 2.04 USD. This implies a price increase of 266.25% is expected in the next year compared to the current price of 0.557.
For the next year, analysts expect an EPS growth of 90% and a revenue growth 509.96% for ICU